Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
Authors:
Open Access
- 28 July 2025
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Abstract
Background: Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rates (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.Methods: This was a single-arm, non-controlled prospective pilot study. Treatment-naive patients with unilateral HR-positive, HER2-negative breast cancer received neoadjuvant radiotherapy (24 Gy/3 F) followed by dalpiciclib and exemestane for six cycles. The primary endpoint was the proportion of patients with residual cancer burden (RCB) score of 0-I. Key secondary endpoints included ORR, breast-conservation rate, biomarker analysis, and safety.Results: All 12 enrolled patients completed the study treatment and surgery. Two (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of tumor specimens showed significant increase of infiltrating T cells rather than alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4–5 AE or death occurred.Conclusions: Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane is effective and tolerable and provides novel insights for the neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as a feasible option for patients with HR-positive, HER2-negative breast cancer.Funding: None.Clinical trial number: ClinicalTrials.gov: NCT05132790Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Neoadjuvant Endocrine Therapy in Clinical PracticeJAMA Oncology, 2021
- Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple MetastasesJAMA Oncology, 2021
- CDK 4/6 inhibitors combined with radiotherapy: A review of literatureClinical and Translational Radiation Oncology, 2021
- Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialThe Lancet Oncology, 2020
- Combination of palbociclib and radiotherapy for glioblastomaCell Death Discovery, 2017
- Awakening the immune system with radiation: Optimal dose and fractionationCancer Letters, 2015
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapyBiochemical and Biophysical Research Communications, 2013
- Eortc QLQ-30International journal of pancreatology, 1998